BackCASI Pharmaceuticals Overview

CASI Pharmaceuticals Total Assets

Track CASI Pharmaceuticals's total assets ($21M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$21.06M
↓ 32.49% YoYΔ $-10.14M vs prior year quarter

Peer trimmed avg / median

Loading

CASI Pharmaceuticals Total Assets History

Loading

CASI Pharmaceuticals vs. peers: Total Assets Comparison

Loading

CASI Pharmaceuticals Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CASI Pharmaceuticals (CASIF) FAQ

CASI Pharmaceuticals posts a total assets of $21M as of June 2026. That compares with $31M in the prior-year period — down 32.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CASI Pharmaceuticals's total assets was $31M. The latest reading is $21M — a 32.5% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Assets is one piece of CASI Pharmaceuticals's financial statement story. At $21M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CASIF's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; CASI Pharmaceuticals's other metric pages and overview cover the third.

Judging CASI Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total assets easier to interpret. Start with $21M here, then scan peer and history charts to see if the gap is persistent.